Medtronic (MDT)
(Delayed Data from NYSE)
$88.58 USD
+0.39 (0.44%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $88.56 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
MDT 88.58 +0.39(0.44%)
Will MDT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MDT
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
MDT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Aug 21, 2024
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics (Revised)
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
Other News for MDT
My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys
Medtronic chairman and CEO Geoff Martha to speak at the Wells Fargo Healthcare Conference
PaceMate? Acquires Medtronic Paceart Optima? System, Bringing Complementary Capabilities to Cardiac Data Management
Let's Have A Look At Buying Dividend Growth Stocks Without Looking, Almost 10 Years Later
Barclays Sticks to Their Buy Rating for Medtronic (MDT)